Ratifi Español Sign in
Ratifi

Federal bills from Congress.gov. State bills from Open States.

HB 2819Session 2025-2026

An Act amending the act of May 17, 1921 (P.L.682, No.284), known as The Insurance Company Law of 1921, in casualty insurance, further providing for coverage for biomarker testing.

Printer's No. PN3985

See other bills
under the
same topic PRINTER'S NO. 3985 THE GENERAL ASSEMBLY OF PENNSYLVANIAHOUSE BILL No.2819 Session of 2026 INTRODUCED BY HANBIDGE, WEBSTER, HILL-EVANS, OTTEN, PIELLI, KINKEAD, RIVERA, SANCHEZ, SHUSTERMAN, GUENST, HOHENSTEIN, McNEILL, DONAHUE, D. WILLIAMS, CEPEDA-FREYTIZ AND PARKER, SEPTEMBER 30, 2026 REFERRED TO COMMITTEE ON INSURANCE, OCTOBER 2, 2026 AN ACTAmending the act of May 17, 1921 (P.L.682, No.284), entitled "An act relating to insurance; amending, revising, and consolidating the law providing for the incorporation of insurance companies, and the regulation, supervision, and protection of home and foreign insurance companies, Lloyds associations, reciprocal and inter-insurance exchanges, and fire insurance rating bureaus, and the regulation and supervision of insurance carried by such companies, associations, and exchanges, including insurance carried by the State Workmen's Insurance Fund; providing penalties; and repealing existing laws," in casualty insurance, further providing for coverage for biomarker testing.The General Assembly of the Commonwealth of Pennsylvania hereby enacts as follows:Section 1. Section 635.9(c) of the act of May 17, 1921 (P.L.682, No.284), known as The Insurance Company Law of 1921, is amended and the section is amended by adding a subsection to read:Section 635.9. Coverage for Biomarker Testing.--* * *(a.1) An insurer that offers, issues or renews a health insurance policy in this Commonwealth shall provide coverage for biomarker testing for preeclampsia for s creening of a covered 12345678910111213141516171819202122 person who is asymptomatic and diagnosis and management of a covered person who is symptomatic. Coverage required under this subsection may not be subject to cost-sharing.* * *(c) The terms in this section shall be given the same definitions as the terms defined pursuant to section 2102 unless otherwise noted. As used in this section, the following words and phrases shall have the meanings given to them in this subsection unless the context clearly indicates otherwise:"Agreement with the Department of Human Services." An agreement between a medical assistance or Children's Health Insurance Program managed care plan and the Department of Human Services."Biomarker." A defined characteristic that is measured as an indicator of normal biological processes, pathogenic processes or responses to an exposure or intervention, including therapeutic interventions. Molecular, histologic, radiologic or physiologic characteristics are types of biomarkers. A biomarker is not an assessment of how a covered person or enrollee feels, functions or survives."Biomarker testing." The analysis of a covered person or enrollee's tissue, blood or other biospecimen for the presence of a biomarker. Biomarker testing includes, but is not limited to, single-analyte tests and multiplex panels performed at a participating in-network laboratory that is CLIA certified by the Federal Food and Drug Administration."Cost-sharing." The share of the health care costs covered by a health insurance policy that an enrollee or covered person pays out-of-pocket. The term includes a deductible, coinsurance, copayment or similar charge. The term does not include a 20260HB2819PN3985 - 2 - 123456789101112131415161718192021222324252627282930 premium, a balance billed amount from an out-of-network provider or the cost of a noncovered service."Medical assistance" or "Children's Health Insurance Program managed care plan." A health care plan that uses a gatekeeper to manage the utilization of health care services, including biomarker testing, by medical assistance or Children's Health Insurance Program enrollees, and integrates the financing and delivery of health care services, including biomarker testing."Preeclampsia." A condition involving all of the following:(1) Persistent high blood pressure that develops after twenty weeks of pregnancy or during the six-week postpartum period.(2) Signs of organ failure, including any of the following:(i) High levels of protein in the urine.(ii) Decreased blood platelets.(iii) Signs of liver trouble.(iv) Fluid in the lungs.(v) Signs of brain trouble such as severe headache, seizure or visual disturbances."Screening." A medical procedure or test for a covered person or enrollee who has yet to display symptoms of a particular disease or condition for the purpose of determining their likelihood of having the disease or condition.Section 2. This act shall apply as follows:(1) For health insurance policies for which either rates or forms are required to be filed with the Federal Government or the Insurance Department, this act shall apply to any policy for which a form or rate is first filed on or after the effective date of this paragraph.(2) For health insurance policies for which neither 20260HB2819PN3985 - 3 - 123456789101112131415161718192021222324252627282930 rates nor forms are required to be filed with the Federal Government or the Insurance Department, this act shall apply to any policy issued or renewed on or after 180 days after the effective date of this paragraph.Section 3. This act shall take effect in 180 days.20260HB2819PN3985 - 4 - 12345

Official text from the Pennsylvania Legislature. Formatting has been adapted for reading on Ratifi.